Osiris Therapeutics, Inc.

Practice Area: 
Stock Symbol: 
Case Status: 
Class Period: 
December 1, 2014 to November 16, 2015

We are investigating possible securities fraud claims against Osiris resulting from inaccurate statements Osiris made regarding its financial performance.

Our investigation focuses on the extent to which Osiris issued false and misleading statements regarding its financial statement, past and future business performance and prospects.  Specifically, the investigation is related to Osiris’s recent disclosure in its 10-Q filing of financial restatements, described by one analyst as showing evidence of "aggressive accounting, particularly in regard to revenue recognition."